Search results
Results from the WOW.Com Content Network
This is a list of investigational sleep drugs, or drugs for the treatment of sleep disorders that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Inhibition of ovulation through an action on the hypothalamic-pituitary-gonadal axis. For a low-dose formulation, this may occur inconsistently in ~50% of cycles. [ 32 ] Intermediate-dose formulations, such as the progestogen-only pill Cerazette (Desogestrel), much more consistently inhibit ovulation in 97–99% of cycles.
Doxylamine succinate is the active ingredient in many over-the-counter sleep aids branded under various names. Doxylamine succinate and pyridoxine (Vitamin B6) are the ingredients of Diclegis, approved by the FDA in April 2013 becoming the only drug approved for morning sickness [46] with a class A safety rating for pregnancy (no evidence of risk).
[215] [216] [217] Accordingly, progestogens, both endogenous and exogenous (i.e., progestins), have antigonadotropic effects, [218] and progestogens in sufficiently high amounts can markedly suppress the body's normal production of progestogens, androgens, and estrogens as well as inhibit fertility (ovulation in women and spermatogenesis in men).
Sleep aids may disrupt brain’s glymphatic system. Researchers also examined if sleep aids might replicate the natural oscillations needed for glymphatic function. They focused their research on ...
Somnifacient (from Latin somnus, sleep [1]), also known as sedatives or sleeping pills, is a class of medications that induces sleep. It is mainly used for treatment of insomnia. Examples of somnifacients include benzodiazepines, barbiturates and antihistamines. Around 2-6% of adults with insomnia use somnifacients to aid sleep. [2]
The list of unapproved chemicals for use as a sleep aid included not only those recommended for banning in 1979, but several others including acetaminophen, aspirin, and passion flower extract. [34] Pharmaceutical manufacturer GlaxoSmithKline owned the Sominex brand in 2011, and announced their decision to divest it in April 2011. [35]
Clomifene citrate (Clomid is a common brand name) is the medication which is most commonly used to treat anovulation. It is a selective estrogen-receptor modulator, affecting the hypothalamic–pituitary–gonadal axis to respond as if there was an estrogen deficit in the body, in effect increasing the production of follicle-stimulating hormone.